- Home
- SRFM vs TNXP Comparison
SRFM vs TNXP Comparison
Compare SRFM & TNXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SRFM
- TNXP
- Stock Information
- Founded
- SRFM 2011
- TNXP 2007
- Country
- SRFM United States
- TNXP United States
- Employees
- SRFM N/A
- TNXP N/A
- Industry
- SRFM Transportation Services
- TNXP Biotechnology: Pharmaceutical Preparations
- Sector
- SRFM Consumer Discretionary
- TNXP Health Care
- Exchange
- SRFM Nasdaq
- TNXP Nasdaq
- Market Cap
- SRFM 15.0M
- TNXP 15.1M
- IPO Year
- SRFM 2023
- TNXP N/A
- Fundamental
- Price
- SRFM $1.94
- TNXP $0.14
- Analyst Decision
- SRFM Hold
- TNXP Strong Buy
- Analyst Count
- SRFM 2
- TNXP 2
- Target Price
- SRFM $2.50
- TNXP $53.50
- AVG Volume (30 Days)
- SRFM 177.6K
- TNXP 35.9M
- Earning Date
- SRFM 11-12-2024
- TNXP 11-07-2024
- Dividend Yield
- SRFM N/A
- TNXP N/A
- EPS Growth
- SRFM N/A
- TNXP N/A
- EPS
- SRFM N/A
- TNXP N/A
- Revenue
- SRFM $111,793,000.00
- TNXP $12,458,000.00
- Revenue This Year
- SRFM $104.61
- TNXP $62.53
- Revenue Next Year
- SRFM $53.30
- TNXP $26.17
- P/E Ratio
- SRFM N/A
- TNXP N/A
- Revenue Growth
- SRFM 392.91
- TNXP N/A
- 52 Week Low
- SRFM $0.90
- TNXP $0.12
- 52 Week High
- SRFM $11.83
- TNXP $22.08
- Technical
- Relative Strength Index (RSI)
- SRFM 65.37
- TNXP 29.54
- Support Level
- SRFM $1.19
- TNXP $0.12
- Resistance Level
- SRFM $1.76
- TNXP $0.21
- Average True Range (ATR)
- SRFM 0.17
- TNXP 0.02
- MACD
- SRFM 0.09
- TNXP 0.02
- Stochastic Oscillator
- SRFM 94.46
- TNXP 21.56
About SRFM Surf Air Mobility Inc.
Surf Air Mobility Inc provides a regional air mobility platform to connect communities sustainably. The company is an electric aviation and air travel company expanding the category of regional air travel and reinventing flying through electrification. The company is building a regional air mobility ecosystem to sustainably connect the world's communities. It generates revenue through air mobility services.
About TNXP Tonix Pharmaceuticals Holding Corp.
Tonix Pharmaceuticals Holding Corp is a biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering. Tonix's development portfolio is focused on central nervous system (CNS) disorders. The company's immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in the areas of rare disease and infectious disease.